SpringWorks Therapeutics, part of Merck KGaA, has received conditional marketing authorization from the European Commission for its drug EZMEKLY® (mirdametinib), marking the first approved treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results